Malcolm Ranson
Cancer Research UK Manchester Institute(GB)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer therapeutics and mechanisms, Lung Cancer Research Studies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research
Most-Cited Works
- → AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer(2014)2,182 cited
- → AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer(2015)2,095 cited
- → Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer(2011)863 cited
- → Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types(2002)831 cited
- → ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial(2002)763 cited
- → Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer(2012)545 cited